15 September 2023
15 September 2023
Commercial clinical trial initiation has decreased over the past five years in the UK however, Greater Manchester has bucked the trend.
The study showed that JADA could control bleeding in both vaginal and caesarean birth, regardless of the cause of the bleeding.
Reduction in the rate of pathological brain atrophy on magnetic resonance imaging scans was observed in the trial.
SP-103 demonstrated safety and tolerability with no serious adverse events reported.
The study was done in partnership with the UK’s National Health Service and included continuous glucose monitoring for participants.
Taldefgrobep is a muscle-targeted recombinant protein targeting two key regulators of muscle mass and adipose tissue.
EDG-7500 can slow down early contraction velocity and improve impaired cardiac relaxation.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
